Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Efficacy of Exosome in Degenerative Meniscal Injury (KNEEXO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05261360
Recruitment Status : Recruiting
First Posted : March 2, 2022
Last Update Posted : March 4, 2022
Sponsor:
Collaborator:
The Scientific and Technological Research Council of Turkey
Information provided by (Responsible Party):
Ayla Eker Sariboyaci, Eskisehir Osmangazi University

Brief Summary:
Comparison of intra-articular administration of synovial fluid-derived mesenchymal stem cells-derived exosomes with synovial fluid-derived mesenchymal stem cells on the same patient.

Condition or disease Intervention/treatment Phase
Knee; Injury, Meniscus (Lateral) (Medial) Meniscus Tear Meniscus Lesion Meniscus; Degeneration Meniscus; Laceration Meniscus Injury, Tibial Knee Injuries Knee Pain Swelling Arthralgia Drug: SF-MSC-EX Drug: SF-MSC Phase 2

Detailed Description:

Mesenchymal stem cell-derived exosomes will be developed and patented as an advanced technology platform as an autologous treatment protocol to repair damaged cartilage tissue. The fact that this treatment is obtained from an autologous source will significantly contribute to the literature in the field of personalized therapy (personalized medicine) and will pave the way for discoveries. Experiences from clinical trials may guide the use of MSC exosomes in other tissue and cell damaged pathologies and immune pathologies or chronic inflammatory diseases.

This study was supported by a grant (1004, 20AG031) from The Scientific and Technological Research Council of Turkey (TUBITAK).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: The study was planned as three arms. One arm will be the control group, and the other two arms will be the experimental group. The control group defines the group that did not receive treatment. Those in the experimental group, who are the participants other than the control group, will occur in both experimental groups. SF-MSC (synovial fluid-derived mesenchymal stem cells) will be applied intraarticularly to the experimental group's right knee, and the experimental group's right knee will be included in the SF-MSC treatment group. SF-MSC-EX (synovial fluid-derived mesenchymal stem cells-derived exosomes) will be applied intraarticularly to the experimental group's left knee, and the experimental group's left knee will be included in the SF-MSC-EX treatment group.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Trial to Investigate Clinical Efficacy of Autologous Synovial Fluid Mesenchymal Stem Cell-Derived Exosome Application in Patients With Degenerative Meniscal Injury
Estimated Study Start Date : March 2022
Estimated Primary Completion Date : March 2024
Estimated Study Completion Date : March 2025

Arm Intervention/treatment
Experimental: SF-MSC-EX Treatment Group (Experimental group's left knees)
The left knee will receive 1 million cells/kg SF-MSC-EX (Synovial fluid mesenchymal stem cell-derived exosome) by intra-articular injection method.
Drug: SF-MSC-EX
Intra-articular administration of synovial fluid-derived mesenchymal stem cells-derived exosomes
Other Name: Intraarticular Exosome Treatment

Experimental: SF-MSC Treatment Group (Experimental group's right knees)
The right knee will receive 1 million cells/kg SF-MSC (Synovial fluid-derived mesenchymal stem cell) by intra-articular injection method.
Drug: SF-MSC
Intra-articular administration of synovial fluid-derived mesenchymal stem cells
Other Name: Intraarticular Stem Cell Treatment

No Intervention: Control Group
Participants who received no treatment were defined as the control group.



Primary Outcome Measures :
  1. Evaluation of Knee Functions [ Time Frame: Up to 12th months ]
    The functional evaluation of the participants will be evaluated on the Tegner-Lysholm knee scoring scale. In Tegner-Lysholm knee scoring, examinations for the knee joint (Limp, support, pain, instability, locking, swelling, stair-climbing, and squatting) will be evaluated, and a maximum of 100 and a minimum of 0 points will be given. According to the evaluation, <65 points are interpreted as bad, 65-83 points as fair, 84-90 points as good, >90 points as excellent. Scores will be recorded by being examined before treatment and at the 6th, and 12th months after treatment. Knee functions of the control group will be evaluated simultaneously, and the effects of treatments on knee function will be determined.

  2. Evaluation of Physical Activity [ Time Frame: Up to 12th months ]
    The physical activity evaluation of the participants will be evaluated with the IPAQ (international physical activity questionnaire) short form. IPAQ short form will be evaluated and recorded before treatment and at the 6th, and 12th months after treatment. The control group's physical activity will be evaluated simultaneously, and the effects of treatments on physical activity will be determined.

  3. Evaluation of Pain [ Time Frame: Up to 12th months ]
    Pain assessment of the participants will be evaluated with VAS (Visual analog scale). The VAS will be evaluated and recorded before treatment and at the 6th, and 12th months after treatment. The physical activity of the control group will be evaluated simultaneously, and the effects of treatments on pain will be determined.

  4. Evaluation of Radiological Images [ Time Frame: Up to 12th months ]
    Participants will receive knee x-ray imaging and knee magnetic resonance imaging before treatment. The same radiological imaging will be performed at the 6th and 12th months after the treatment. At the same time, the same radiological imaging will be performed on the control group, and the effects of treatments on radiological imaging will be evaluated.

  5. Evaluation of Cytokine Levels and Cytokine Genes Analyzes [ Time Frame: Up to 12th months ]
    Before treatment and at the 6th and 12th months after treatment, cytokine levels (IL-10, IL-6, TNF-α, IL-8, IL-1β, IFN-ɣ, IL-2, IL-4, IL-13, MCP-1, VEGF) and gene analyzes (IL-10, IL-6, TNF-α, IL-8, IL-1β, IFN-ɣ, IL-2, IL-4, IL-13, MCP-1, IL-1ra, MIP-1b, CTGF, TGFβ3, BMP-2, BMP-4, IGF-1, IGF-2, PDGF, EGF, and VEGF genes) will be checked in the samples taken from the synovial fluid and blood. Samples will be taken from the control group along with the treatment group. In this way, the effects of treatments on cytokine levels will be evaluated.

  6. Evaluation of Edema [ Time Frame: Up to 12th months ]
    Edema in both knees will be measured using a tape measure by marking the midpoints of both patellae. Pre-treatment measurements will be recorded. Measurements of both knees will be recorded at 6 months and 12 months after treatment. The knees of the patients not receiving treatment will be measured simultaneously, and the changes will be compared.

  7. Evaluation of Knee Joint Range of Motion [ Time Frame: Up to 12th months ]
    The range of motion of both knees will be measured using the "Baseline Digital Absolute+Axis Goniometer." Knee extension measurements will be made with the patient in the supine position and flexion in the prone position. Pre-treatment measurements will be recorded. Post-treatment 6th and 12th-month measurements will also be recorded. Measurements of patients not receiving treatment will be recorded simultaneously, and changes will be compared.

  8. Monitoring of treatment-related complications [ Time Frame: Up to 12th months ]
    Adverse effects and complications will be observed in the treatment group, except for the expected local reactions (redness, swelling, bruising, etc.) after the application.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   30 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Accepting the Informed Consent Form
  • Degenerative meniscus damage grade 1, 2 or 3 on MRI in both right and left knees, and also the patient does not want surgical treatment
  • Patients with the same degenerative meniscus grade in both knees
  • Patients with ongoing pain
  • Patients without a history of malignancy
  • Absence of signs of unstable meniscus tear such as snagging or locking
  • Patients with stage 0, 1 or 2 gonarthrosis according to Kellgren-Lawrence gonarthrosis staging
  • Patients without lower extremity malalignment

Exclusion Criteria:

  • Patients whose treatment method was explained and who did not accept the method
  • Patients outside the working-age range
  • Congenital lesion
  • Patients requiring surgical treatment (e.g. bucket handle tear and locked knee)
  • Active inflammatory or connective tissue disease is thought to affect the patient's pain (eg lupus, rheumatoid arthritis, fibromyalgia)
  • Local or systemic infection
  • Pregnant or breastfeeding women
  • Active endocrine disorder that may affect the assessment of patient's pain (eg, hypothyroidism, diabetes)
  • Active neurological disorder that may affect the assessment of the patient's pain (eg, peripheral neuropathy, multiple sclerosis)
  • Active heart disease
  • Presence of a pacemaker
  • Conditions where MR-I is contraindicated
  • Patients with stage 3 or 4 gonarthrosis according to Kellgren-Lawrence gonarthrosis staging
  • Patients with lower extremity malalignment
  • Patients with signs of unstable meniscus tear such as snagging or locking

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05261360


Contacts
Layout table for location contacts
Contact: Ayla Eker Sarıboyacı, AssocProfDr. +905382696420 aylaekersariboyaci@yahoo.com

Locations
Layout table for location information
Turkey
Eskisehir Osmangazi University Recruiting
Eskisehir, Turkey, 26040
Contact: Ayla Eker Sariboyaci, AssocProfDr    +905382696420    aylaekersariboyaci@yahoo.com   
Principal Investigator: Ulukan Inan, Prof.Dr.         
Sub-Investigator: Ayla Eker Sariboyaci, AssocProfDr         
Sub-Investigator: Onur Uysal, AssocProfDr         
Sponsors and Collaborators
Eskisehir Osmangazi University
The Scientific and Technological Research Council of Turkey
Investigators
Layout table for investigator information
Study Chair: Ayla Eker Sarıboyacı, AssocProfDr. Cell Therapy and Stem Cell Production Application and Research Center (ESTEM)
Study Director: Onur Uysal, AssocProfDr. Cell Therapy and Stem Cell Production Application and Research Center (ESTEM)
Principal Investigator: Ulukan İnan, ProfDr. Eskisehir Osmangazi University Faculty of Medicine Department of Orthopedy and Traumatology
Publications:
Layout table for additonal information
Responsible Party: Ayla Eker Sariboyaci, Assoc. Prof. Dr., Eskisehir Osmangazi University
ClinicalTrials.gov Identifier: NCT05261360    
Other Study ID Numbers: 56733164/203
First Posted: March 2, 2022    Key Record Dates
Last Update Posted: March 4, 2022
Last Verified: March 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Results will be reported after the completion of the study.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Ayla Eker Sariboyaci, Eskisehir Osmangazi University:
Meniscal injury
Exosome
Mesenchymal Stem Cell
Synovial Fluid
Regeneration
Additional relevant MeSH terms:
Layout table for MeSH terms
Arthralgia
Wounds and Injuries
Lacerations
Knee Injuries
Tibial Meniscus Injuries
Leg Injuries
Joint Diseases
Musculoskeletal Diseases
Pain
Neurologic Manifestations